LGALS3 and cancer: To do so, we used TD-139, a thiodigalactoside small-molecule inhibitor that targets the Galectin-3 carbohydrate-binding domain (Fig. 4A) and is currently being evaluated in clinical studies for its therapeutic potential in fibrotic, cancer and inflammatory disorders (26, 28–30, 40).